Gavi is working with Alliance partners UNICEF and WHO to ensure that the infrastructure is in place, and the technical support available, to make sure COVID-19 vaccines can be safely delivered to all those who need them. The COVAX AMC and associated support to the eligible countries that apply will build on Gavi’s two decades of experience delivering life-saving vaccines to more than half of the world’s population, including in the hardest to reach communities. The COVAX AMC is critical to ensuring equitable access to COVID-19 vaccines, regardless of income level – and requires an urgent investment of US$ 2 billion, from sovereign donors, philanthropies and the private sector, by the end of 2020.

Gavi is coordinating the development and implementation of the COVAX AMC, the financing instrument that will support the participation of 92 lower-middle and low-income economies in the COVAX Facility. Guided by an allocation framework being developed by WHO, the COVAX Facility will then equitably distribute these doses to help protect the most at-risk groups in all participating countries. This means the COVAX Facility, by pooling purchasing power from all countries that participate, will have rapid access to doses of safe and effective vaccines as soon as they receive regulatory approval. The COVAX Facility will make investments across a broad portfolio of promising vaccine candidates (including those being supported by CEPI) to make sure at-risk investment in manufacturing happens now. Gavi is coordinating the development and implementation of the COVAX Facility, the global procurement mechanism of COVAX. For any questions, or to submit an application, please contact COVAX Facility Shipments for humanitarian agencies, including UN organisations, Red Cross and Red Crescent, International and national non-governmental and civil society organisations, are subject to successful conclusion of contracts with manufacturers, including on indemnity and liability-related arrangements.Īpplying for the COVAX Humanitarian BufferĬOVAX Humanitarian Buffer applications are for doses, devices and delivery funding, as required. Supply constraints affecting the COVAX Facility will also impact the availability of doses to the Humanitarian Buffer. N.B. While application review, approval, prioritisation and allocation will be undertaken on an ongoing basis by the IASC decision-making body, applicants are advised that shipment of doses is contingent on available supply and successful contracting with manufacturers:

GHC Position on COVID-19 Vaccination in Humanitarian SettingsĬOVID-19 immunization in refugees and migrants: WHO Interim Guidance

Joint Note on COVID-19 Vaccination in Fragile Settings Frequently asked questions: COVAX Humanitarian Buffer

Buffer gate project red